Amneal Pharmaceuticals (NASDAQ:AMRX – Get Rating) is one of 939 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Amneal Pharmaceuticals to similar businesses based on the strength of its earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends.
This is a breakdown of recent recommendations and price targets for Amneal Pharmaceuticals and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Amneal Pharmaceuticals Competitors||6386||21019||43246||868||2.54|
Institutional & Insider Ownership
33.4% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 45.4% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 26.8% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 14.6% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This table compares Amneal Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Amneal Pharmaceuticals Competitors||-3,144.42%||-1,577.63%||-9.15%|
Risk and Volatility
Amneal Pharmaceuticals has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals’ competitors have a beta of 1.12, indicating that their average share price is 12% more volatile than the S&P 500.
Valuation & Earnings
This table compares Amneal Pharmaceuticals and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Amneal Pharmaceuticals||$2.09 billion||$10.62 million||174.00|
|Amneal Pharmaceuticals Competitors||$1.86 billion||$249.36 million||-1.50|
Amneal Pharmaceuticals has higher revenue, but lower earnings than its competitors. Amneal Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Amneal Pharmaceuticals beats its competitors on 7 of the 10 factors compared.
Amneal Pharmaceuticals Company Profile (Get Rating)
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.